Owners, management and financials
CVR: 38180045
Secondary names: Novo Nordisk Region Europe Pharmaceuticals A/S, Novo Nordisk North West Europe Pharmaceuticals A/S
Previous names: Novo Nordisk Region Europe Pharmaceuticals A/S
EUR 2,504,841,000
Revenue
Net result: EUR 118,803,000
NOVO NORDISK REGION EUROPE A/S (100%)
CVR · view owners
Mads Wilhelm Øckenholt Larsen
Board: Mark Iain Hicken (chair) and 2 members
CVR · view management
Active
Founded 14 November 2016
CVR · view overview
298 employees
CVR · 2026
Director registered: Mads Wilhelm Øckenholt Larsen
CVR · 17/01/2025
View the full event history
Novo Nordisk Denmark A/S is a Danish company of the type Aktieselskab based in København S, founded in 2016. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Novo Nordisk Region Europe Pharmaceuticals A/S. The management consists of Mads Wilhelm Øckenholt Larsen. The board consists of Mark Iain Hicken (chair), David Marcus Svensson and Jeppe Theisen. The company is owned by NOVO NORDISK REGION EUROPE A/S. The company has 298 employees (2026). In 2025, the company reported revenue of EUR 2,504,841,000 and a net result of EUR 118,803,000 compared with DKK 86,129,000 the year before. Equity in the 2025 report amounted to EUR 134,570,000.
Source: annual report 2025, Danish Business Authority
Novo Nordisk Denmark A/S exhibits a strong financial trajectory, with significant revenue growth from 373.9 million DKK in 2021 to 2.5 billion EUR in 2025. Profitability has also improved, with net profits rising from 21.4 million DKK in 2021 to 118.8 million EUR in 2025, indicating a robust operational performance. The company's equity has increased from 36.99 million DKK in 2021 to 134.57 million EUR, reflecting a solid financial foundation. However, the rapid growth in revenue and profit may raise concerns about sustainability and market competition within the pharmaceutical wholesale industry. Overall, Novo Nordisk Denmark A/S is positioned as a significant player in the market, leveraging its strong financial health to capitalize on industry opportunities.
AI-generated summary · Generated 20/08/2026
Selskabets formål er at markedsføre, promovere, importere, sælge og distribuere farmaceutiske og medicinske produkter, repræsentation af selskaber, supporterende services og forretningsassistance til interessenter i Europa, rådgivning og services i forbindelse med registrering af farmaceutiske produkter, forskning og udvikling af farmaceutiske produkter, kliniske forsøg, samt anden hertil knyttet virksomhed der ikke er forbudt ved lov. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 2.5B EUR | 118.8M EUR | 1.4B EUR | 134.6M EUR | 299 | |
| 202401/01/2024 – 31/12/2024 | 2.4B | 86.1M | 1.1B | 101.8M | 294 | |
| 202301/01/2023 – 31/12/2023 | 2B | 82M | 1.2B | 97.6M | 236 | |
| 202201/01/2022 – 31/12/2022 | 509.9M | 33.5M | 446.7M | 49.1M | 200 | |
| 202101/01/2021 – 31/12/2021 | 373.9M | 21.4M | 283.4M | 37M | 176 | |
| 202001/01/2020 – 31/12/2020 | 330.1M | 21.3M | 585M | 36.6M | 152 | |
| 201901/01/2019 – 31/12/2019 | 363.9M | 5.3M | 149.6M | 15.3M | 65 | |
| 201801/01/2018 – 31/12/2018 | 341.9M | 4.2M | 130M | 10.1M | 69 |
Compared to 403 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
10 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorThe CVR number of Novo Nordisk Denmark A/S is 38180045.
Novo Nordisk Denmark A/S is owned by NOVO NORDISK REGION EUROPE A/S.
The management of Novo Nordisk Denmark A/S consists of Mads Wilhelm Øckenholt Larsen.
The board of Novo Nordisk Denmark A/S consists of Mark Iain Hicken, David Marcus Svensson and Jeppe Theisen, with Mark Iain Hicken as chair.
In 2025, Novo Nordisk Denmark A/S reported revenue of EUR 2,504,841,000.
Novo Nordisk Denmark A/S had 298 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
As of October 20, 2026, Mark Iain Hicken has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 20, 2026, Jonas Emil Kongshøj Larsen has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2025. Revenue came to DKK 2,504,841,000, and the net result was DKK 118,803,000.
As of March 6, 2026, Jeppe Theisen has joined the board of directors of Novo Nordisk Denmark A/S.
As of March 6, 2026, David Marcus Svensson has joined the board of directors of Novo Nordisk Denmark A/S.
As of March 6, 2026, Malin Eva Maria Andreasen has left the board of directors of Novo Nordisk Denmark A/S.
As of March 6, 2026, Anders Rytter Mikkelsen has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.1184.a" issued by Amgros I/S worth 103,180,000 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.1185.a" issued by Amgros I/S worth 99,225,000 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.1186.a" issued by Amgros I/S worth 220,000,000 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.1187.a" issued by Amgros I/S worth 480,900,000 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.1180.a" issued by Amgros I/S worth 1,563,800,000 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.708.b" issued by Amgros I/S worth 321,891,182 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2026 1.1559.b" issued by Amgros I/S worth 527,000,000 DKK.
Novo Nordisk Denmark A/S has published its annual report for 2024. Revenue came to DKK 2,367,751,000, and the net result was DKK 86,129,000.
As of January 17, 2025, Mads Wilhelm Øckenholt Larsen is registered as director of Novo Nordisk Denmark A/S.
As of January 17, 2025, Jeppe Theisen has stepped down as director of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has won the tender "Amgros 2025 1.702.b" issued by Amgros I/S worth 64,099,999 DKK.
Novo Nordisk Denmark A/S has published its annual report for 2023. Revenue came to DKK 2,017,346,469, and the net result was DKK 81,997,613.
Novo Nordisk Denmark A/S has won the tender "Amgros 2024 1.1187.a" issued by Amgros I/S worth 14,700,000 DKK.
Novo Nordisk Denmark A/S has won the tender "Amgros 2024 1.1186.a" issued by Amgros I/S worth 548,800,000 DKK.
As of April 2, 2024, Malin Eva Maria Andreasen has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 2, 2024, Anders Rytter Mikkelsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 2, 2024, Tomas Haagen has left the board of directors of Novo Nordisk Denmark A/S.
As of April 2, 2024, Morten Berger Engelund has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2022. Revenue came to DKK 509,919,862, and the net result was DKK 33,547,904.
As of October 26, 2022, Jonas Emil Kongshøj Larsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 26, 2022, Frederik Kier has left the board of directors of Novo Nordisk Denmark A/S.
As of October 26, 2022, Jeppe Theisen is registered as director of Novo Nordisk Denmark A/S.
As of October 26, 2022, Kasper Bødker Mejlvang has stepped down as director of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2021. Revenue came to DKK 373,940,044, and the net result was DKK 21,405,179.
Novo Nordisk Denmark A/S has published its annual report for 2020. Revenue came to DKK 330,145,351, and the net result was DKK 21,277,960.
As of April 15, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Denmark A/S.
As of April 15, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2019. Revenue came to DKK 363,935,809, and the net result was DKK 5,251,810.
As of April 1, 2020, Frederik Kier has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 1, 2020, Morten Berger Engelund has joined the board of directors of Novo Nordisk Denmark A/S.
As of April 1, 2020, Mads Veggerby Lausten has left the board of directors of Novo Nordisk Denmark A/S.
As of April 1, 2020, Matt Joseph Regan has left the board of directors of Novo Nordisk Denmark A/S.
As of December 1, 2019, Kasper Bødker Mejlvang is registered as director of Novo Nordisk Denmark A/S.
As of November 30, 2019, Morten Berger Engelund has stepped down as director of Novo Nordisk Denmark A/S.
As of October 1, 2019, Mads Veggerby Lausten has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2019, Matt Joseph Regan has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2019, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Denmark A/S.
On October 1, 2019, the company changed its name from Novo Nordisk Region Europe Pharmaceuticals A/S to Novo Nordisk Denmark A/S.
As of September 30, 2019, Matt Joseph Regan has left the board of directors of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its annual report for 2018. Revenue came to DKK 341,939,236, and the net result was DKK 4,213,051.
As of October 1, 2018, Tomas Haagen has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2018, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of October 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Denmark A/S.
As of September 30, 2018, Karsten Munk Knudsen has left the board of directors of Novo Nordisk Denmark A/S.
As of May 15, 2018, Morten Berger Engelund is registered as director of Novo Nordisk Denmark A/S.
As of May 15, 2018, Steffen Hillebrandt Thejls has stepped down as director of Novo Nordisk Denmark A/S.
Novo Nordisk Denmark A/S has published its interim report for the period November 14, 2016 to December 31, 2017.
As of January 1, 2018, Steffen Hillebrandt Thejls is registered as director of Novo Nordisk Denmark A/S.
As of January 1, 2018, Mads Veggerby Lausten has stepped down as director of Novo Nordisk Denmark A/S.
As of September 15, 2017, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Karsten Munk Knudsen has joined the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Matt Joseph Regan has joined the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Jesper Brandgaard has left the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Lars Fruergaard Jørgensen has left the board of directors of Novo Nordisk Denmark A/S.
As of September 15, 2017, Karsten Munk Knudsen has stepped down as director of Novo Nordisk Denmark A/S.
As of September 14, 2017, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Denmark A/S.
As of November 14, 2016, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, Jesper Brandgaard has joined the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, Lars Fruergaard Jørgensen has joined the board of directors of Novo Nordisk Denmark A/S.
As of November 14, 2016, Mads Veggerby Lausten is registered as director of Novo Nordisk Denmark A/S.
As of November 14, 2016, Karsten Munk Knudsen is registered as director of Novo Nordisk Denmark A/S.
As of November 14, 2016, NOVO NORDISK REGION EUROPE A/S is registered as an owner of Novo Nordisk Denmark A/S with an ownership share of 100%.
Novo Nordisk Denmark A/S was founded on November 14, 2016.

Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.

Selskabets formål er at drive virksomhed med handel og produktion samt hermed beslægtet virksomhed.


Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.

Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Companies in the same industry and area
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
CVR 37285145